Assignee
MIRATI THERAPEUTICS INC
US·40 granted patents·63 pending applications·139 citations·filing 2016–2025
Top patents by PatentIndex Score
103 records- 0197US10689377B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Jun 23, 2020·16 cites·57 claims
- 0296US11453683B1KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·13 cites·84 claims
- 0396US11091495B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Aug 17, 2021·4 cites·26 claims
- 0496US10125134B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Nov 13, 2018·43 cites·9 claims
- 0593US10633381B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Apr 28, 2020·8 cites·7 claims
- 0692US12421253B2Tetrahydropyridopyrimidine pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·1 cites·29 claims
- 0792US11964989B2KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·2 cites·19 claims
- 0892US11220509B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jan 11, 2022·2 cites·27 claims
- 0991US11267812B2KRAS G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Mar 8, 2022·11 cites·34 claims
- 1091US10647715B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted May 12, 2020·10 cites·9 claims
- 1191US9809541B2LSD1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2016·Granted Nov 7, 2017·11 cites·62 claims
- 1289US11999753B2Tetrahydropyridopyrimidine pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jun 4, 2024·1 cites·5 claims
- 1389US11890285B2Combination therapiesMIRATI THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·4 cites·43 claims
- 1486US10266542B2EZH2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Apr 23, 2019·6 cites·40 claims
- 1584US12208099B2Combination therapiesMIRATI THERAPEUTICS INC·Filed 2019·Granted Jan 28, 2025·3 cites·9 claims
- 1684US11479551B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Oct 25, 2022·1 cites·30 claims
- 1782US11548888B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Jan 10, 2023·1 cites·9 claims
- 1882US2026035389A1Tetrahydropyridopyrimidine pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1982US2025282787A1SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORSMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2082US2024101553A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2181US11932633B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Mar 19, 2024·2 cites·41 claims
- 2280US12371435B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Jul 29, 2025·0 cites·20 claims
- 2379US12281113B2Crystalline forms of a KRas G12C inhibitorMIRATI THERAPEUTICS INC·Filed 2024·Granted Apr 22, 2025·0 cites·30 claims
- 2478US2023373999A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2577US12304915B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted May 20, 2025·0 cites·81 claims
- 2677US2024309020A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2775US2025270220A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2874US2025073241A1Combination Therapies Using PRMT5 Inhibitors for the Treatment of CancerMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2973US2025282778A1Crystalline forms of a kras g12c inhibitorMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3073US2024423987A1Combination Therapies Using PRMT5 Inhibitors for the Treatment of CancerMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3172US2026097038A1COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITHMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3272US2023054883A1MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3371US12383503B2Adagrasib solid pharmaceutical compositionsMIRATI THERAPEUTICS INC·Filed 2024·Granted Aug 12, 2025·0 cites·30 claims
- 3471US2025108055A1Combination therapiesMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3570US12171765B2Combination therapies using PRMT5 inhibitors for the treatment of cancerMIRATI THERAPEUTICS INC·Filed 2022·Granted Dec 24, 2024·0 cites·18 claims
- 3670US12128048B2Combination therapies using PRMT5 inhibitors for the treatment of cancerMIRATI THERAPEUTICS INC·Filed 2022·Granted Oct 29, 2024·0 cites·16 claims
- 3770US2025388606A1Azaquinazoline pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3870US2026083679A1Adagrasib solid pharmaceutical compositionsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3969US12286431B2Crystalline forms of a KRas G12C inhibitorMIRATI THERAPEUTICS INC·Filed 2021·Granted Apr 29, 2025·0 cites·19 claims
- 4068US12398154B2Azaquinazoline pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Aug 26, 2025·0 cites·49 claims
- 4168US11492351B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Nov 8, 2022·0 cites·27 claims
- 4268US2020262837A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4368US2024156821A1Combination therapiesMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4467US11702418B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Jul 18, 2023·0 cites·72 claims
- 4567US2024391882A1Substituted QuinoxalinesMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4666US12336995B2Combination therapiesMIRATI THERAPEUTICS INC·Filed 2019·Granted Jun 24, 2025·0 cites·36 claims
- 4766US11485738B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Nov 1, 2022·0 cites·18 claims
- 4866US2024374525A1Adagrasib solid pharmaceutical compositionsMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4966US2025382290A1Salts of sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 5066US2026015350A1Azaquinazoline pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 103 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MIRATI THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →